JNJ vs ABT
By Alex · Tickerpine
Johnson & Johnson vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | ABT |
|---|---|---|
| Price | $285.75 | $108.52 |
| Market cap | $687.89B | $187.95B |
| P/E ratio | 43.4 | 40.5 |
| ROE | 20.02% | 9.14% |
| Profit margin | 16.20% | 9.75% |
| Revenue growth | 5.90% | 14.50% |
| Dividend yield | 1.88% | 2.32% |
| Beta | 0.20 | 0.54 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs ABT in plain English
- JNJ is the bigger company — about 3.7× the market cap of ABT.
- ABT is cheaper on earnings (P/E 40.5 vs 43.4).
- JNJ earns a higher return on equity (20% vs 9%).
- ABT is growing revenue faster (14% vs 6%).
- ABT has the higher dividend yield (2.32% vs 1.88%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.